Jaundice (Hyperbilirubinemia)

Introduction for MCCQE1 Preparation

Jaundice, or icterus, is the yellowish discoloration of the skin, sclerae, and mucous membranes caused by hyperbilirubinemia. For the MCCQE1, understanding the pathophysiology and having a structured approach to the differential diagnosis is crucial. This topic falls under the Internal Medicine and Hepatology domains.

As a Canadian medical graduate, you must be proficient in distinguishing between isolated hyperbilirubinemia and liver disease, as well as differentiating between hepatocellular and cholestatic patterns. This guide aligns with the CanMEDS Medical Expert role, focusing on diagnostic reasoning and management within the Canadian healthcare system.

💡

Clinical Pearl: Jaundice typically becomes clinically visible when serum bilirubin levels exceed 50 µmol/L (approx. 3 mg/dL). Scleral icterus is often the first sign due to the high affinity of elastin for bilirubin.

Pathophysiology & Metabolism

Understanding the metabolic pathway of bilirubin is essential for classifying the type of jaundice.

Key Definitions

Unconjugated (Indirect) Bilirubin: Lipid-soluble, toxic to the CNS (kernicterus in neonates), bound to albumin. Not excreted in urine.
Conjugated (Direct) Bilirubin: Water-soluble, non-toxic, excreted in bile and urine. Dark urine suggests conjugated hyperbilirubinemia.

Classification of Jaundice

The most effective way to approach jaundice for the MCCQE1 is by anatomical classification: Pre-hepatic, Hepatic, and Post-hepatic.

Pre-hepatic

Pre-hepatic (Hemolysis & Metabolism)

Mechanism: Overproduction of bilirubin or impaired uptake/conjugation.

Key Feature: Elevated Unconjugated Bilirubin.
Urine: Normal color (no bilirubin), but may have increased urobilinogen.
Common Causes:
- Hemolysis: Autoimmune hemolytic anemia, Malaria (consider in travelers), Sickle Cell Disease.
- Impaired Conjugation: Gilbert’s Syndrome (very common), Crigler-Najjar Syndrome.

Canadian Epidemiology Note: Gilbert’s Syndrome

Affects up to 5-10% of the population. Benign condition. Jaundice is often precipitated by stress, fasting, or illness. No treatment required.

Clinical Evaluation

1. History Taking (MCCQE1 Focus)

When taking a history for a jaundiced patient, focus on risk factors and distinguishing features.

Onset and Duration: Acute vs. Chronic.
Associated Symptoms:
- Constitutional: Fever, weight loss (malignancy), fatigue.
- Abdominal pain: RUQ pain (biliary pathology). Painless jaundice is a red flag for malignancy.
- Pruritus: Suggests cholestasis.
Stool and Urine: Pale stools and dark urine indicate conjugated hyperbilirubinemia.
Risk Factors (Social History):
- Alcohol consumption (quantity and frequency).
- IV drug use, tattoos, sexual history (Hepatitis B/C).
- Travel history (Hepatitis A/E, Malaria).
- Medications (Acetaminophen, antibiotics, herbal supplements).

2. Physical Examination

Look for stigmata of chronic liver disease (CLD) and signs of liver failure.

Sign	Suggests
Asterixis	Hepatic encephalopathy (Liver failure)
Spider Angiomata	Hyperestrogenism (CLD)
Palmar Erythema	Hyperestrogenism (CLD)
Caput Medusae	Portal Hypertension
Courvoisier’s Sign	Palpable, non-tender gallbladder (Pancreatic cancer)
Kayser-Fleischer Rings	Wilson’s Disease
Xanthelasma	Chronic cholestasis (e.g., PBC)

Diagnostic Approach

Follow this step-by-step algorithm to investigate jaundice, reflecting standard Canadian practice guidelines.

Step 1: Isolate the Hyperbilirubinemia

Order Total and Direct Bilirubin.

If Direct > 50% of Total: Conjugated Hyperbilirubinemia.
If Direct < 15-20% of Total: Unconjugated Hyperbilirubinemia.

Step 2: Analyze Liver Enzymes (If Conjugated)

Determine the pattern of injury:

Hepatocellular Pattern: ALT/AST elevation predominates.
Cholestatic Pattern: ALP/GGT elevation predominates.

Step 3: First-Line Imaging

In Canada, Abdominal Ultrasound is the initial modality of choice for biliary obstruction.

Dilated ducts: Suggests extrahepatic obstruction (stones, tumors).
Normal ducts: Suggests intrahepatic cholestasis or hepatocellular disease.

Step 4: Specific Testing based on Pattern

Hepatocellular: Viral serology (Hep A/B/C), Autoimmune markers (ANA, ASMA), Ferritin, Ceruloplasmin.
Cholestatic: AMA (PBC), MRCP/ERCP (PSC, Stones, Tumors).
Unconjugated: Reticulocyte count, Haptoglobin, LDH, Peripheral smear (Hemolysis workup).

Canadian Guidelines & Choosing Wisely

It is vital to integrate Choosing Wisely Canada recommendations into your MCCQE1 study plan.

Don’t order ANA as a screening test in patients with non-specific symptoms (fatigue, musculoskeletal pain) without clinical suspicion of autoimmune disease.
Hepatitis C Screening: Current Canadian guidelines recommend screening based on risk factors, though some provinces advocate for birth cohort screening (1945–1975). Be aware of the shift towards universal screening discussions.
Alcohol Use Disorder: Reference Canada’s Guidance on Alcohol and Health (2023).

Interpreting Liver Enzymes: The R-Factor

To objectively distinguish hepatocellular from cholestatic injury: $R = \frac{(ALT / ULN)}{(ALP / ULN)}$

R > 5: Hepatocellular injury
R < 2: Cholestatic injury
2 < R < 5: Mixed pattern (ULN = Upper Limit of Normal)

Key Points to Remember for MCCQE1

Painless Jaundice + Weight Loss = Pancreatic Cancer until proven otherwise (Refer for CT Pancreas).
Gilbert’s Syndrome: Elevated unconjugated bilirubin, normal LFTs, normal CBC. Diagnosis of exclusion; reassurance is the management.
Alcoholic Hepatitis: AST:ALT ratio is typically 2:1 (AST rarely > 300 U/L).
Viral Hepatitis: ALT > AST, levels often > 1000 U/L in acute infection.
Primary Biliary Cholangitis (PBC): Middle-aged female, pruritus, elevated ALP, Anti-Mitochondrial Antibody (AMA) positive.
Primary Sclerosing Cholangitis (PSC): Strongly associated with Ulcerative Colitis. “Beads on a string” appearance on MRCP.

Sample Question

Stem: A 52-year-old female presents to the clinic with a 3-month history of generalized pruritus and fatigue. She denies any abdominal pain, fever, or weight loss. Her past medical history is significant for hypothyroidism. She does not smoke or consume alcohol. Physical examination reveals excoriations on her extremities and xanthelasma on her eyelids. There is no scleral icterus, but hepatomegaly is noted.

Laboratory investigations reveal:

Total Bilirubin: 28 µmol/L (Normal: <22 µmol/L)
ALP: 450 U/L (Normal: 40-129 U/L)
AST: 45 U/L (Normal: <35 U/L)
ALT: 52 U/L (Normal: <35 U/L)

Which one of the following is the most appropriate next step to confirm the diagnosis?

Options:

A. Endoscopic Retrograde Cholangiopancreatography (ERCP)
B. Anti-nuclear Antibody (ANA)
C. Anti-mitochondrial Antibody (AMA)
D. Abdominal Computed Tomography (CT)
E. Liver Biopsy

Explanation

The correct answer is:

C. Anti-mitochondrial Antibody (AMA)

Explanation: This clinical vignette is classic for Primary Biliary Cholangitis (PBC).

Demographics: Typically affects middle-aged women.
Presentation: Insidious onset of fatigue and pruritus (often preceding jaundice). Xanthelasma is common due to hyperlipidemia associated with cholestasis.
Labs: Cholestatic pattern (markedly elevated ALP with mild/normal aminotransferases).
Diagnosis: The serologic hallmark of PBC is the presence of Anti-mitochondrial Antibodies (AMA), which are present in 90-95% of patients. A positive AMA with a cholestatic liver profile is sufficient for diagnosis without a liver biopsy in most cases.

Why other options are incorrect:

A (ERCP): Used for large duct obstruction (e.g., stones, PSC). PBC affects small intralobular bile ducts, which are not visualized on ERCP.
B (ANA): While ANA can be positive in PBC, it is non-specific. It is the hallmark of Autoimmune Hepatitis, which would present with a hepatocellular pattern (high AST/ALT).
D (CT): Imaging is useful to rule out extrahepatic obstruction, but ultrasound is usually first-line. Furthermore, the specific serologic test (AMA) provides a definitive diagnosis for the suspected condition.
E (Liver Biopsy): Reserved for cases where AMA is negative or to stage the degree of fibrosis/cirrhosis. It is not the initial confirmatory step given the high specificity of AMA.

References

Medical Council of Canada. MCCQE Part I Clinical Decision-Making and Multiple-Choice Question Objectives.
Burak, K. W., et al. (2020). Management of cholestatic liver diseases: A consensus statement by the Canadian Association for the Study of the Liver. Canadian Liver Journal.
Choosing Wisely Canada. Internal Medicine: Five Things Physicians and Patients Should Question.
Feld, J. J., et al. (2018). The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver. CMAJ.
Toronto Centre for Liver Disease. Liver Disease Guidelines. University Health Network.